Ticker | $ Bought |
---|---|
bristol-myers squibb co | 17,992,000 |
biogen inc | 15,531,300 |
eli lilly & co | 14,866,400 |
roivant sciences ltd | 13,117,000 |
verona pharma plc | 10,158,400 |
madrigal pharmaceuticals inc | 7,949,520 |
summit therapeutics inc | 7,716,000 |
halozyme therapeutics inc | 7,657,200 |
Ticker | % Inc. |
---|---|
centessa pharmaceuticals plc | 184 |
tarsus pharmaceuticals inc | 82.22 |
perrigo co plc | 62.81 |
teva pharmaceutical inds ltd | 37.09 |
amgen inc | 31.27 |
Ticker | % Reduced |
---|---|
royalty pharma plc | -53.34 |
newamsterdam pharma company | -34.41 |
bridgebio pharma inc | -30.28 |
agios pharmaceuticals inc | -21.97 |
insmed inc | -11.62 |
ultragenyx pharmaceutical in | -6.76 |
Ticker | $ Sold |
---|---|
viridian therapeutics inc | -12,051,700 |
akero therapeutics inc | -6,398,600 |
vera therapeutics inc | -8,994,910 |
moderna inc | -8,212,050 |
neumora therapeutics inc. | -1,590,000 |
johnson & johnson | -20,474,100 |
sarepta therapeutics inc | -15,108,300 |
janux therapeutics inc | -6,424,800 |
Cutter Capital Management, LP has about 100% of it's holdings in Healthcare sector.
Sector | % |
---|---|
Healthcare | 100 |
Cutter Capital Management, LP has about 44.3% of it's portfolio invested in the large-cap and mega-cap stocks.
Category | % |
---|---|
MID-CAP | 40.7 |
LARGE-CAP | 37.8 |
SMALL-CAP | 13.1 |
MEGA-CAP | 6.5 |
UNALLOCATED | 2 |
About 63.3% of the stocks held by Cutter Capital Management, LP either belong to S&P 500 or RUSSELL 2000 index.
Index | % |
---|---|
Others | 36.8 |
RUSSELL 2000 | 35.4 |
S&P 500 | 27.9 |
This heatmap illustrates the top 50 positions within the fund's portfolio.
Cutter Capital Management, LP has 21 stocks in it's portfolio. About 62.8% of the portfolio is in top 10 stocks. TEVA proved to be the most loss making stock for the portfolio. RPRX was the most profitable stock for Cutter Capital Management, LP last quarter.
Last Reported on: 15 May, 2025Ticker | Namesorted descending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
---|---|---|---|---|---|---|---|---|
BMY | bristol-myers squibb co | 7.84 | 295,000 | 17,992,000 | new | |||
Historical Trend of BRISTOL-MYERS SQUIBB CO Position Held By Cutter Capital Management, LPWhat % of Portfolio is BMY?:Number of BMY shares held:Change in No. of Shares Held: | ||||||||
AMGN | amgen inc | 6.78 | 50,000 | 15,577,500 | added | 31.27 | ||
BIIB | biogen inc | 6.76 | 113,500 | 15,531,300 | new | |||
LLY | eli lilly & co | 6.47 | 18,000 | 14,866,400 | new | |||
INSM | insmed inc | 6.19 | 186,384 | 14,219,200 | reduced | -11.62 | ||
RARE | ultragenyx pharmaceutical in | 5.98 | 379,303 | 13,734,600 | reduced | -6.76 | ||
BBIO | bridgebio pharma inc | 5.88 | 390,644 | 13,504,600 | reduced | -30.28 | ||
PRGO | perrigo co plc | 5.86 | 479,517 | 13,445,700 | added | 62.81 | ||
ROIV | roivant sciences ltd | 5.71 | 1,300,000 | 13,117,000 | new | |||
TEVA | teva pharmaceutical inds ltd | 5.37 | 801,806 | 12,323,800 | added | 37.09 | ||
RPRX | royalty pharma plc | 4.84 | 356,894 | 11,110,100 | reduced | -53.34 | ||
TARS | tarsus pharmaceuticals inc | 4.59 | 205,000 | 10,530,800 | added | 82.22 | ||
VRNA | verona pharma plc | 4.42 | 160,000 | 10,158,400 | new | |||
MDGL | madrigal pharmaceuticals inc | 3.46 | 24,000 | 7,949,520 | new | |||
SMMT | summit therapeutics inc | 3.36 | 400,000 | 7,716,000 | new | |||
HALO | halozyme therapeutics inc | 3.33 | 120,000 | 7,657,200 | new | |||
CYTK | cytokinetics inc | 3.06 | 175,000 | 7,033,250 | new | |||
AGIO | agios pharmaceuticals inc | 3.00 | 235,350 | 6,895,760 | reduced | -21.97 | ||
CNTA | centessa pharmaceuticals plc | 2.62 | 418,127 | 6,012,670 | added | 184 | ||
RCUS | arcus biosciences inc | 2.50 | 731,818 | 5,744,770 | new | |||